Developments in the management of idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF), a chronic progressive fibrotic interstitial lung disease (ILD) of unknown origin,(1) has seen significant change in its management over the last 15 years.(2) In addition, two antifibrotic drugs that have 'orphan designation' from the European Medicines Agency, ▼pirfenidone and ▼nintedanib, have received marketing authorisation approval for use in the UK.(3-5) Here we provide an overview of IPF and the importance of supportive and symptomatic care, and review the evidence for antifibrotic therapy.